Skip to main content

Remote Job Finders (RJF)

Roche insists amylin obesity drug still valuable for patients who ‘don’t want side effects’

Roche and Zealand Pharma announced last month that their amylin analog petrelintide elicited a 9% placebo-controlled weight reduction at 42 weeks—falling far below analyst and investor expectations.
Scroll to top